Navigation Links
Eureka Therapeutics raises $21 million in series c to expand cancer immunotherapy pipeline
Date:9/23/2014

Eureka Therapeutics, Inc. announced today that the Company has secured $21 million in a Series C Financing. The new funding will be used to expand the Company's cancer immunotherapy pipeline and advance its lead programs to clinical development. New investor Yuan Capital led the round, with participation from Majuven and all existing major investors, including Acorn Campus Ventures, Suma Venture and Harbinger Venture Capital.

Eureka is engaged in the discovery and development of fully-human antibodies engineered to mimic the functions of a T cell receptor, a key component of the immune system. These therapeutic antibodies are designed to recognize proteins residing inside of cancer cells, and mobilize a patient's immune system to recognize and kill the diseased cell.

"This new funding will allow us to expand and advance our drug pipeline, as well as explore the synergistic effects of our drug candidates with other immunotherapies and immune modulators," said Cheng Liu, PhD, President and CEO of Eureka Therapeutics. "This moves us closer to our goal of providing cancer patients with safer and more effective treatments through novel immunotherapies."

"We are pleased to have the continued confidence and support of our existing investors, and we welcome our new investors," added Dr. Liu.

Earlier this year, the Company announced a license agreement with Novartis for the development and commercialization of ESK1, a preclinical-stage monoclonal antibody for the treatment of leukemia and other cancers. The antibody, targeting the intracellular protein WT1, was developed under a collaborative effort between Eureka Therapeutics and Memorial Sloan-Kettering Cancer Center.


'/>"/>

Contact: Elisa Pan
admin@eurekainc.com
510-654-7045
Eureka Therapeutics, Inc.

Source:Eurekalert

Page: 1

Related biology news :

1. EUREKA grant to fund development of new optogenetic technique for mapping neural networks at UMMS
2. Study shows Hera Therapeutics compound combats HPV types that cause most cervical cancer
3. Human Longevity, Inc. and Celgene Cellular Therapeutics Sign License Agreement to Develop and Commercialize Placental Stem Cell Population, PSC-100 for Multiple Therapeutic Applications
4. Splice-switching oligonucleotide therapeutics is new method for editing gene transcript
5. Industry group release testing recommendations for oligonucleotide-based therapeutics
6. Nanomerics, UCL, H Lundbeck & Exeter University to research new brain therapeutics
7. Next-generation glaucoma therapeutics hold considerable promise
8. FASEB announces 2014 SRC: Translational Neuroimmunology: From Mechanisms to Therapeutics
9. Emerging class of therapeutics represents a coming wave for developers and manufacturers
10. Natura Therapeutics product shown to improve decision making skills in older adults
11. Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2018)... ... July 25, 2018 , ... Boston ... executives on September 4, 2018 at The Hilton Boston Back Bay Hotel. This ... business development experiences and dissect the most relevant deals in biotech. , George ...
(Date:7/26/2018)... ... July 26, 2018 , ... The Conference Forum has confirmed the agenda for ... 24, 2018 at the Marriott Copley Place in Boston, MA. , Daniel Karlin, MD, ... as program chair to lead the discussion on how and when to implement mobile/digital ...
(Date:7/25/2018)... ... ... pioneering Duchenne muscular dystrophy clinical trial is now recruiting patients at two sites in ... the need to enroll patients. , “There is no cure for Duchenne, and ... a clinical trial,” said Catherine Jayasuriya, the founder and executive director of Coalition Duchenne, ...
Breaking Biology News(10 mins):
(Date:7/31/2018)... ... July 31, 2018 , ... Leading regenerative veterinary medicine company, ... and using adipose tissue-derived stem cells to treat or prevent inflammation at the ... covers Canada specifically, VetStem has been issued similar patents that cover the United ...
(Date:7/25/2018)... Tenn. (PRWEB) , ... July 25, 2018 , ... ... research results on the significant impact of a biofield energy treated nutraceutical to ... The preclinical research assessed biomarkers for skin health and reported the following results:, ...
(Date:7/25/2018)... , ... July 25, 2018 , ... ... (IoT) Systems Innovator, joined the board of the Indiana India Business Council (IIBC), ... unanimously elected today by the current board of directors, McDonald joins an impressive ...
(Date:7/22/2018)... ... July 19, 2018 , ... ... professional has joined their team. With more than ten years of strategic, result-oriented ... deliver his expertise as CallTower’s Channel Director for the Southwest and Mountain region. ...
Breaking Biology Technology: